This study found that prophylactic depletion of Tregs by anti-CD25 treatment prior to primary tumor engraftment and followed by primary tumor resection resulted in protection of 80% of mice against secondary tumor growth re-challenge (172). The gene discussed is IL2RA; the disease is neoplasm.